UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms

Clinical infectious diseases, 2008-06, Vol.46 (11), p.1683-1693

2008

Volltextzugriff (PDF)

Clinical, economic and societal impact of antibiotic resistance

Expert opinion on pharmacotherapy, 2015-02, Vol.16 (2), p.151-153

Barriere, Steven L

2015

Volltextzugriff (PDF)

Challenges in the Design and Conduct of Clinical Trials for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: An Industry Perspective

Clinical infectious diseases, 2010-08, Vol.51 (Supplement-1), p.S4-S9

Barriere, Steven L.

2010

Volltextzugriff (PDF)

Genotypic Characteristics of Staphylococcus aureus Isolates from a Multinational Trial of Complicated Skin and Skin Structure Infections

Journal of Clinical Microbiology, 2008-02, Vol.46 (2), p.678-684

2008

Volltextzugriff (PDF)

TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

Antimicrobial Agents and Chemotherapy, 2012-11, Vol.56 (11), p.5476-5483

2012

Volltextzugriff (PDF)

Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria

Clinical infectious diseases, 2005-06, Vol.40 (11), p.1601-1607

2005

Volltextzugriff (PDF)

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

Antimicrobial Agents and Chemotherapy, 2006-03, Vol.50 (3), p.862-867

2006

Volltextzugriff (PDF)

Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections

Antimicrobial Agents and Chemotherapy, 2012-04, Vol.56 (4), p.2067-2073

2012

Volltextzugriff (PDF)

Presence of Genes Encoding the Panton-Valentine Leukocidin Exotoxin Is Not the Primary Determinant of Outcome in Patients with Complicated Skin and Skin Structure Infections Due to Methicillin-Resistant Staphylococcus aureus: Results of a Multinational Trial

Journal of Clinical Microbiology, 2009-12, Vol.47 (12), p.3952-3957

2009

Volltextzugriff (PDF)

Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics

Antimicrobial Agents and Chemotherapy, 2008-01, Vol.52 (1), p.92-97

2008

Volltextzugriff (PDF)

Presence of Genes Encoding Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome in Patients with Hospital-Acquired Pneumonia Due to Staphylococcus aureus

Journal of Clinical Microbiology, 2012-03, Vol.50 (3), p.848-856

2012

Volltextzugriff (PDF)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

Infectious diseases and therapy, 2019-09, Vol.8 (3), p.445-452

2019

Volltextzugriff (PDF)

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia

Future microbiology, 2014-03, Vol.9 (3), p.281-289

Barriere, Steven L

2014

Volltextzugriff (PDF)

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures

The American journal of surgery, 2009-06, Vol.197 (6), p.791-796

2009

Volltextzugriff (PDF)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

Clinical infectious diseases, 2011-01, Vol.52 (1), p.31-40

2011

Volltextzugriff (PDF)

Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

Antimicrobial agents and chemotherapy, 2014-04, Vol.58 (4), p.2030-2037

2014

Volltextzugriff (PDF)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment

European journal of clinical pharmacology, 2015-06, Vol.71 (6), p.707-714

2015

Volltextzugriff (PDF)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus

Clinical infectious diseases, 2015-03, Vol.60 (5), p.787-796

2015

Volltextzugriff (PDF)

An overview of mortality risk prediction in sepsis

Critical care medicine, 1995-02, Vol.23 (2), p.376-393

1995

Volltextzugriff (PDF)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

BMC infectious diseases, 2014-05, Vol.14 (1), p.289-289, Article 289

2014

Volltextzugriff (PDF)

Variability in telavancin cross-reactivity among vancomycin immunoassays

Antimicrobial agents and chemotherapy, 2014-12, Vol.58 (12), p.7093-7097

2014

Volltextzugriff (PDF)

Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality

Clinical infectious diseases, 2015-09, Vol.61 (suppl 2), p.S87-S93

2015

Volltextzugriff (PDF)

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance

Antimicrobial agents and chemotherapy, 2015-10, Vol.59 (10), p.6170-6174

2015

Volltextzugriff (PDF)

Assessment of Telavancin Minimal Inhibitory Concentrations by Revised Broth Microdilution Method in Phase 3 Complicated Skin and Skin-Structure Infection Clinical Trial Isolates

Diagnostic microbiology and infectious disease, 2017-03, Vol.87 (3), p.268-271

2017

Volltextzugriff (PDF)

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections

Future microbiology, 2010-12, Vol.5 (12), p.1765-1773

Barriere, Steven L

2010

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(139)
Bücher
(1)

Sprache

Englisch
(139)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(90)
Humans
(79)
Pharmacology & Pharmacy
(52)
Male
(41)
Biological And Medical Sciences
(38)
Adult
(37)
Female
(37)
Microbiology
(37)
Medical Sciences
(34)
Infectious Diseases
(31)
Middle Aged
(31)
Pharmacology. Drug Treatments
(29)
Anti-Bacterial Agents - Therapeutic Use
(27)
Aged
(24)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(23)
Staphylococcus Aureus
(22)
Aminoglycosides - Therapeutic Use
(19)
Telavancin
(19)
Vancomycin - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms

Clinical, economic and societal impact of antibiotic resistance

Challenges in the Design and Conduct of Clinical Trials for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: An Industry Perspective

Genotypic Characteristics of Staphylococcus aureus Isolates from a Multinational Trial of Complicated Skin and Skin Structure Infections

TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections

Presence of Genes Encoding the Panton-Valentine Leukocidin Exotoxin Is Not the Primary Determinant of Outcome in Patients with Complicated Skin and Skin Structure Infections Due to Methicillin-Resistant Staphylococcus aureus: Results of a Multinational Trial

Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics

Presence of Genes Encoding Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome in Patients with Hospital-Acquired Pneumonia Due to Staphylococcus aureus

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus

An overview of mortality risk prediction in sepsis

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

Variability in telavancin cross-reactivity among vancomycin immunoassays

Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance

Assessment of Telavancin Minimal Inhibitory Concentrations by Revised Broth Microdilution Method in Phase 3 Complicated Skin and Skin-Structure Infection Clinical Trial Isolates

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections

Suchergebnisse filtern